{
  "query": "SNY",
  "resolved": {
    "ticker": "SNY",
    "cik": "0001121404",
    "title": "Sanofi"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "Sanofi (SNY) — PHASE2 primary completion in ~176 days",
      "entity": "Sanofi",
      "ticker": "SNY",
      "cik": "0001121404",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)",
        "nctId": "NCT06111586",
        "date": "2027-04-28"
      },
      "observed": {
        "event": "primary completion in ~176 days",
        "nctId": "NCT06111586"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06111586",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "Sanofi (SNY) — PHASE2 protocol updated 11 days ago",
      "entity": "Sanofi",
      "ticker": "SNY",
      "cik": "0001121404",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease",
        "nctId": "NCT07688213",
        "date": "2029-07-31"
      },
      "observed": {
        "event": "protocol updated 11 days ago",
        "nctId": "NCT07688213"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07688213",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "Sanofi",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": []
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-11-03T09:00:20.748Z"
}